BRPI0408854A - veìculo de disfarce de sabor para partìculas de oxazolidinona revestidas - Google Patents

veìculo de disfarce de sabor para partìculas de oxazolidinona revestidas

Info

Publication number
BRPI0408854A
BRPI0408854A BRPI0408854-9A BRPI0408854A BRPI0408854A BR PI0408854 A BRPI0408854 A BR PI0408854A BR PI0408854 A BRPI0408854 A BR PI0408854A BR PI0408854 A BRPI0408854 A BR PI0408854A
Authority
BR
Brazil
Prior art keywords
particles
oxazolidinone
coated
vehicle
flavor masking
Prior art date
Application number
BRPI0408854-9A
Other languages
English (en)
Inventor
Jennifer K Fredrickson
Julia A Kistka
Joseph P Reo
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0408854A publication Critical patent/BRPI0408854A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"VEìCULO DE DISFARCE DE SABOR PARA PARTìCULAS DE OXAZOLIDINONA REVESTIDAS". A presente invenção é direcionada para as formulações secas de partículas de oxazolidinona revestidas, tais como as partículas de linezolida revestidas, que, quando suspensas em uma solução aquosa, disfarçam o sabor da oxazolidinona no veículo de suspensão resultante. Especificamente, uma mistura de açúcares na formulação, compreendendo sorbitol e sacarose, inibe o transporte em massa da oxazolidinona a partir das partículas para o veículo de suspensão. As formulações secas das partículas de oxazolidinona revestidas, as suspensões das mesmas e os métodos de utilização destas para tratar ou prevenir infecções por bactérias gram-positivas são todos divulgados.
BRPI0408854-9A 2003-03-31 2004-03-19 veìculo de disfarce de sabor para partìculas de oxazolidinona revestidas BRPI0408854A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45938203P 2003-03-31 2003-03-31
PCT/IB2004/000921 WO2004087108A1 (en) 2003-03-31 2004-03-19 Taste-masking vehicle for coated oxazolidinone particles

Publications (1)

Publication Number Publication Date
BRPI0408854A true BRPI0408854A (pt) 2006-04-04

Family

ID=33131883

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408854-9A BRPI0408854A (pt) 2003-03-31 2004-03-19 veìculo de disfarce de sabor para partìculas de oxazolidinona revestidas

Country Status (7)

Country Link
US (1) US20040191326A1 (pt)
EP (1) EP1610764A1 (pt)
JP (1) JP2006522089A (pt)
BR (1) BRPI0408854A (pt)
CA (1) CA2519869A1 (pt)
MX (1) MXPA05010629A (pt)
WO (1) WO2004087108A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
WO2010046933A2 (en) 2008-10-22 2010-04-29 Rubicon Research Private Limited Pharmaceutical compositions of taste-masked linezolid
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
KR20170056573A (ko) * 2014-09-19 2017-05-23 유프락시아 파마수티컬스 인코포레이티드 치료제의 고도로 국소화된 방출을 위한 주입가능한 미립자
TR201808237T4 (tr) 2015-10-27 2018-07-23 Eupraxia Pharmaceuticals Inc Lokal anestetiklerin sürekli salım formülasyonları.
CN105853351B (zh) * 2016-03-31 2019-02-22 重庆华邦制药有限公司 利奈唑胺口服混悬液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
SE8605515D0 (sv) * 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
KR100257418B1 (ko) * 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
TW271400B (pt) * 1992-07-30 1996-03-01 Pfizer
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (en) * 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
WO1996003976A1 (en) * 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
KR20010015910A (ko) * 1998-01-23 2001-02-26 로렌스 티. 마이젠헬더 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation

Also Published As

Publication number Publication date
MXPA05010629A (es) 2005-12-12
JP2006522089A (ja) 2006-09-28
WO2004087108A1 (en) 2004-10-14
US20040191326A1 (en) 2004-09-30
EP1610764A1 (en) 2006-01-04
CA2519869A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
AR021074A1 (es) COMPOSICIoN FARMACÉUTICA DE MOXIFLOXACINA, PROCEDIMIENTO PARA SU PRODUCCIoN, Y USO DE DICHA COMPOSICIoN PARA PREPARAR UN MEDICAMENTO ANTIBACTERIANO.
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
CY1113283T1 (el) Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
ATE538774T1 (de) Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
WO2009154304A3 (en) A pharmaceutical composition comprising rebamipide
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
RU2010123174A (ru) Профилактика и лечение вторичных инфекций после вирусной инфекции
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
BR0112330A (pt) Formulações de macrolìdeos para inalação e seus usos para o tratamento de infecções endobrÈnquicas
BRPI0408854A (pt) veìculo de disfarce de sabor para partìculas de oxazolidinona revestidas
BR0306738A (pt) Processo e aparelho para preparar partìculas cristalinas de uma substância, população de partìculas, e, composição farmacêutica
WO2005041919A3 (de) Medikamentöse gezielte lokale lipolyse
BR0310046A (pt) Atenuação de metapneumovìrus
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
ATE267816T1 (de) Tan-1057 derivate
PT1223972E (pt) Suspensao de uma proteina de epi-hne processo para a sua preparacao aerossol de po anidro derivado dela composicoes farmaceuticas contendo a referida suspensao ou aerossol e as suas utilizacoes
BRPI0514380A (pt) amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
TW200738599A (en) New pleuromutilin derivative and its use
MX2019002386A (es) Uso de oligosacaridos de leche humana en el engorde de terneros.
BRPI0411524A (pt) formulação farmacêutica de amoxicilina e clavulanato, uso de carboximetilcelulose de sódio, e, método de tratar infecção bacteriana em pacientes pediátricos
HUP0202888A2 (hu) Xenogén oligo- és/vagy poliribonukleotidokat tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.